Expert consensus on the management of breast cancer antibody-drug conjugates infusion

Abstract

Antibody-drug conjugates (ADC) are a new class of antineoplastic agents whose structure is composed of a monoclonal antibody covalently attached to a cytotoxic drug via a chemical linker. The introduction and clinical application of ADC change the treatment pattern of human epidermal growth factor receptor 2 (HER2) and triple-negative breast cancer, which is put forward new requirements for the standardized use and management of ADC drugs for medical staff. ADC drugs infusion norms and the prevention and management of adverse reactions are important prerequisites for ensuring drug efficacy and safety. Therefore, the Breast Cancer Case Manager Branch of the Chinese Medical Education Association and the consensus formulation group on targeted drug infusion norms jointly formulated an expert consensus on management of breast cancer antibody-drug conjugates infusion norms. The aim is to provide practical guidance and the early prevention and timely management of related adverse reactions of ADC drugs such as Trastuzumab Emtansine, Trastuzumab Deruxtecan, and Sacituzumab Govitecan for clinical staff.